Formulation Development
Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study for the Treatment of Osteogenesis Imperfecta
Ultragenyx Pharmaceutical Inc. recently announced the first patient has been dosed in a clinical study for the treatment of Osteogenesis Imperfecta (OI) in patients….
Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined With Capecitabine (Next-Generation Capecitabine)
Processa Pharmaceuticals, Inc. recently announced the first patient with advanced, refractory gastrointestinal cancer has been dosed in its amended maximum tolerated dose (MTD) Phase 1B…
BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology
BioXcel Therapeutics, Inc. recently announced the formation of wholly owned subsidiary OnkosXcel Therapeutics, Inc. to develop transformative medicines in….
KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate
KemPharm, Inc. recently announced the first subject has been dosed in a Phase 1 clinical trial designed to assess the relative cardiovascular safety of serdexmethylphenidate…
TFF Pharmaceuticals Announces Safety & Pharmacokinetic Data From Phase 1 Study of Niclosamide Inhalation Powder
TFF Pharmaceuticals, Inc. recently announced safety and pharmacokinetic (PK) data from its Phase 1 study of Niclosamide Inhalation Powder, which is being developed for the…
Revive Therapeutics Announces Publication of Research Data With Bucillamine in COVID-19
Revive Therapeutics Ltd. recently announced the publication of a scientific article evaluating the impact of medication, including Bucillamine, on antibody response to SARS-CoV-2 mRNA vaccines…
NEC & Shionogi Enter Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
NEC Corporation and Shionogi & Co., Ltd. recently announced the execution of a strategic research collaboration agreement for the development of a novel hepatitis B therapeutic….
Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study for MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma & Non-Small Cell Lung Cancer
Black Diamond Therapeutics, Inc. recently announced the dosing of the first patient in the Phase 1 study evaluating BDTX-1535, a MasterKey inhibitor of epidermal growth…
Ocugen to Commercialize COVAXIN in Mexico, Rights Now Encompassing All of North America
Ocugen, Inc. and Bharat Biotech recently announced they have entered into an amendment to their Co-development, Supply and Commercialization Agreement to expand Ocugen’s exclusive….
Kinnate Biopharma Announces First Patient Dosed in Phase 1 Clinical Trial
Kinnate Biopharma Inc. recently announced the first patient has commenced treatment in its Phase 1 KN-4802 (NCT05242822) clinical trial evaluating its lead Fibroblast Growth Factor…
Top Results for Vetter in University of St. Gallen Benchmarking
Vetter successfully participated in a lab benchmarking with its incoming goods lab in the past year. The University of St. Gallen (HSG) participated in the…
Catalent Adds New High-Throughput Encapsulation Manufacturing Suites at Kansas City, Missouri, Facility
Catalent recently announced that it has completed the installation and commissioning of four new high throughput "high-bay" CGMP manufacturing suites at its facility in Kansas…
Halozyme to Acquire Antares Pharma to Create a Specialty Product & Drug Delivery Leader
Halozyme Therapeutics, Inc. and Antares Pharma, Inc. recently announced the companies have entered into a definitive agreement pursuant to which Halozyme will acquire Antares for….
Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial for Multiple Sclerosis
Imcyse recently announced the first patient has been dosed in the adaptive Phase 1/2 clinical trial evaluating Imotope IMCY-0141 in patients with relapsing-remitting multiple sclerosis….
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
BriaCell Therapeutics Corp. recently announced the US FDA has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT, for the treatment of metastatic breast cancer…
Artelo Biosciences Reports Positive Preclinical Results for Lead Program in Cancer-Related Cachexia
Artelo Biosciences, Inc. recently announced ART27.13, a peripherally selective G-Protein Coupled Receptor (GPCR) full agonist currently in clinical development for cancer-related anorexia, shows promising preclinical…
ChemoCentryx Reports PK & PD Results From Ongoing Phase 1 Trial of Orally Administered PD-L1 Inhibitor
ChemoCentryx, Inc. recently announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase 1 clinical study of…
Geocann & Averix Bio Form Strategic Partnership to Supply Global Marketplace With Pharmaceutical API Phytocannabinoid Ingredients Formulated With Proven Delivery System
Geocann recently announced a strategic partnership with Averix Bio that will bring US-produced API phytocannabinoid ingredients and clinically proven bioavailable formulations to the global marketplace.…
Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency & ENPP1 Deficiency
Inozyme Pharma, Inc. recently announced the first patient has been dosed in its Phase 1/2 clinical trial of INZ-701 in adult patients with ABCC6 Deficiency…
Caladrius Biosciences Treats First Patient in the Phase 1b Trial for the Treatment of Diabetic Kidney Disease
Caladrius Biosciences, Inc. recently announced the first patient has been treated in its Phase 1b open-label, proof-of-concept study of CLBS201 for the treatment of diabetic…
